New Zealand rheumatologist Professor Lisa Stamp has been recognised for her breakthrough research in gout.

Last night she was awarded the Medicines New Zealand 2017 Value of Medicines Award for her world first  trial which demonstrated that increasing the dose of allopurinol over time was more effective than standard dosing, without increasing side effects (link to study here).

Louisa Wall MP, Jill Drake, Lisa Stamp and Dr Graeme Jarvis

“Previously patients with chronic kidney disease would not be effectively managed with allopurinol due to concerns of the possibility of increased risk of side effects. This research reveals that with gradual dose increases of allopurinol over time, we can help these patients to better manage this disease without the further risk of side effects” said Professor Stamp.

“This study will have a high impact on patient care benefiting not only New Zealand patients but patients internationally who are suffering from this crippling disease” said Dr Lee Mathias, Chair of Medicines New Zealand.